218 related articles for article (PubMed ID: 35725455)
21. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
Sato F; Ito A; Ishida T; Mori F; Takino H; Inagaki A; Ri M; Kusumoto S; Komatsu H; Iida S; Okada N; Inagaki H; Ueda R
Cancer Immunol Immunother; 2010 Dec; 59(12):1791-800. PubMed ID: 20714721
[TBL] [Abstract][Full Text] [Related]
22. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20.
Evers M; Rösner T; Dünkel A; Jansen JHM; Baumann N; Ten Broeke T; Nederend M; Eichholz K; Klausz K; Reiding K; Schewe DM; Kellner C; Peipp M; Leusen JHW; Valerius T
Blood Adv; 2021 Oct; 5(19):3807-3820. PubMed ID: 34525171
[TBL] [Abstract][Full Text] [Related]
23. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
[TBL] [Abstract][Full Text] [Related]
24. Bispecific mAb
Stadlbauer K; Andorfer P; Stadlmayr G; Rüker F; Wozniak-Knopp G
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563599
[TBL] [Abstract][Full Text] [Related]
25. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
[TBL] [Abstract][Full Text] [Related]
26. A rheumatoid factor paradox: inhibition of rituximab effector function.
Jones JD; Shyu I; Newkirk MM; Rigby WF
Arthritis Res Ther; 2013 Jan; 15(1):R20. PubMed ID: 23351360
[TBL] [Abstract][Full Text] [Related]
27. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
[TBL] [Abstract][Full Text] [Related]
28. Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20.
Lee SM; Min SW; Kwon HS; Bae GD; Jung JH; Park HI; Lee SH; Lim CS; Ko BJ; Lee JC; Jung ST
Sci Rep; 2023 Oct; 13(1):18275. PubMed ID: 37880350
[TBL] [Abstract][Full Text] [Related]
29. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab.
Felberg A; Taszner M; Urban A; Majeranowski A; Jaskuła K; Jurkiewicz A; Stasiłojć G; Blom AM; Zaucha JM; Okrój M
Front Immunol; 2020; 11():584509. PubMed ID: 33329558
[TBL] [Abstract][Full Text] [Related]
31. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
32. Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.
You T; Hu W; Ge X; Shen J; Qin X
Cell Mol Immunol; 2011 Mar; 8(2):157-63. PubMed ID: 21258360
[TBL] [Abstract][Full Text] [Related]
33. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
[TBL] [Abstract][Full Text] [Related]
34. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
35. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
37. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
Zhou X; Hu W; Qin X
Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
[TBL] [Abstract][Full Text] [Related]
38. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
40. Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.
Li HF; Wu C; Chen T; Zhang G; Zhao H; Ke CH; Xu Z
Int J Nanomedicine; 2015; 10():4783-96. PubMed ID: 26257518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]